{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T23:59:34Z","timestamp":1776988774105,"version":"3.51.4"},"reference-count":187,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,12,18]],"date-time":"2010-12-18T00:00:00Z","timestamp":1292630400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s00109-010-0709-z","type":"journal-article","created":{"date-parts":[[2010,12,17]],"date-time":"2010-12-17T08:15:27Z","timestamp":1292573727000},"page":"343-361","source":"Crossref","is-referenced-by-count":21,"title":["Emerging therapeutic approaches in the management of retinal angiogenesis and edema"],"prefix":"10.1007","volume":"89","author":[{"given":"An","family":"Truong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tien Y.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Levon M.","family":"Khachigian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,12,18]]},"reference":[{"key":"709_CR1","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/S0161-6420(01)00823-5","volume":"108","author":"H Buch","year":"2001","unstructured":"Buch H, Vinding T, Nielsen NV (2001) Prevalence and causes of visual impairment according to World Health Organization and United States criteria in an aged, urban Scandinavian population: the Copenhagen City Eye Study. Ophthalmology 108:2347\u20132357","journal-title":"Ophthalmology"},{"key":"709_CR2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archopht.122.4.477","volume":"122","author":"N Congdon","year":"2004","unstructured":"Congdon N, O\u2019Colmain B, Klaver CC, Klein R, Mu\u00f1oz B, Friedman DS, Kempen J, Taylor HR, Mitchell P, EDPR Group (2004) Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122:477\u2013485","journal-title":"Arch Ophthalmol"},{"key":"709_CR3","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ajo.2003.11.069","volume":"137","author":"R Klein","year":"2004","unstructured":"Klein R, Peto T, Bird A, Vannewkirk MR (2004) The epidemiology of age-related macular degeneration. Am J Ophthalmol 137:486\u2013495","journal-title":"Am J Ophthalmol"},{"key":"709_CR4","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0161-6420(01)01008-9","volume":"109","author":"J Rodriguez","year":"2002","unstructured":"Rodriguez J, Sanchez R, Munoz B, West SK, Broman A, Snyder RW, Klein R, Quigley H (2002) Causes of blindness and visual impairment in a population-based sample of U.S. Hispanics. Ophthalmology 109:737\u2013743","journal-title":"Ophthalmology"},{"key":"709_CR5","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1001\/archopht.126.8.1091","volume":"126","author":"TY Wong","year":"2008","unstructured":"Wong TY, Chong EW, Wong WL, Rosman M, Aung T, Loo JL, Shen S, Loon SC, Tan DT, Tai ES et al (2008) Prevalence and causes of low vision and blindness in an urban malay population: the Singapore Malay Eye Study. Arch Ophthalmol 126:1091\u20131099","journal-title":"Arch Ophthalmol"},{"key":"709_CR6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/archophthalmol.2009.58","volume":"127","author":"DB Rein","year":"2009","unstructured":"Rein DB, Wittenborn JS, Zhang X, Honeycutt AA, Lesesne SB, Saaddine J, VHC-ES Group (2009) Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch Ophthalmol 127:533\u2013540","journal-title":"Arch Ophthalmol"},{"key":"709_CR7","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1001\/archopht.126.12.1740","volume":"126","author":"JB Saaddine","year":"2008","unstructured":"Saaddine JB, Honeycutt AA, Narayan KM, Zhang X, Klein R, Boyle JP (2008) Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005\u20132050. Arch Ophthalmol 126:1740\u20131747","journal-title":"Arch Ophthalmol"},{"key":"709_CR8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0039-6257(79)90158-9","volume":"23","author":"J Cunha-Vaz","year":"1979","unstructured":"Cunha-Vaz J (1979) The blood-ocular barriers. Surv Ophthalmol 23:279\u2013296","journal-title":"Surv Ophthalmol"},{"key":"709_CR9","first-page":"183","volume":"86","author":"G Ryan","year":"1977","unstructured":"Ryan G, Majno G (1977) Acute inflammation. A review. Am J Pathol 86:183\u2013276","journal-title":"Am J Pathol"},{"key":"709_CR10","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.preteyeres.2009.06.001","volume":"28","author":"H Xu","year":"2009","unstructured":"Xu H, Chen M, Forrester JV (2009) Para-inflammation in the aging retina. Prog Retin Eye Res 28:348\u2013368","journal-title":"Prog Retin Eye Res"},{"key":"709_CR11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1463-1326.2007.00795.x","volume":"10","author":"S Ejaz","year":"2008","unstructured":"Ejaz S, Chekarova I, Ejaz A, Sohail A, Lim CW (2008) Importance of pericytes and mechanisms of pericyte loss during diabetes retinopathy. Diabetes Obes Metab 10:53\u201363","journal-title":"Diabetes Obes Metab"},{"key":"709_CR12","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0002-9394(01)00967-9","volume":"131","author":"VITPS Group","year":"2001","unstructured":"VITPS Group (2001) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization\u2013verteporfin in photodynamic therapy report 2. Am J Ophthalmol 131:541\u2013560","journal-title":"Am J Ophthalmol"},{"key":"709_CR13","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/eye.2009.335","volume":"24","author":"M Blumenkranz","year":"2010","unstructured":"Blumenkranz M (2010) Optimal current and future treatments for diabetic macular oedema. Eye (Lond) 24:428\u2013434","journal-title":"Eye (Lond)"},{"key":"709_CR14","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1001\/jama.298.8.902","volume":"298","author":"Q Mohamed","year":"2007","unstructured":"Mohamed Q, Gillies M, Wong T (2007) Management of diabetic retinopathy: a systematic review. JAMA 298:902\u2013916","journal-title":"JAMA"},{"key":"709_CR15","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, AS Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432\u20131444","journal-title":"N Engl J Med"},{"key":"709_CR16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"D Brown","year":"2009","unstructured":"Brown D, Michels M, Kaiser P, Heier J, Sy J, Ianchulev T, AS Group (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116:57\u201365","journal-title":"Ophthalmology"},{"key":"709_CR17","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MS Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431","journal-title":"N Engl J Med"},{"key":"709_CR18","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","volume":"376","author":"N Cheung","year":"2010","unstructured":"Cheung N, Mitchell P, Wong TY (2010) Diabetic retinopathy. Lancet 376:124\u2013136","journal-title":"Lancet"},{"key":"709_CR19","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","volume":"117","author":"DM Brown","year":"2010","unstructured":"Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY, CRUISE Investigators (2010) Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1124\u20131133.e1","journal-title":"Ophthalmology"},{"key":"709_CR20","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","volume":"117","author":"PA Campochiaro","year":"2010","unstructured":"Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG, BRAVO Investigators (2010) Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Opthalmology 117:1102\u20131112.e1","journal-title":"Opthalmology"},{"issue":"3","key":"709_CR21","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1167\/iovs.09-4496","volume":"51","author":"C Framme","year":"2009","unstructured":"Framme C, Panagakis G, Birngruber R (2009) Effects on choroidal neovascularizations after anti-VEGF upload using intravitreal ranibizumab as determined by spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci 51(3):1671\u20131676","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"709_CR22","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.ophtha.2008.12.018","volume":"116","author":"AJ Witkin","year":"2009","unstructured":"Witkin AJ, Vuong LN, Srinivasan V, Gorczynska I, Reichel E, Baumal CR, Rogers AH, Schuman JS, Fujimoto JG, Duker JS (2009) High-speed ultrahigh resolution optical coherence tomography before and after ranibizumab for age-related macular degeneration. Ophthalmology 116:956\u2013963","journal-title":"Ophthalmology"},{"key":"709_CR23","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0140-6736(07)61104-0","volume":"370","author":"TY Wong","year":"2007","unstructured":"Wong TY, Liew G, Mitchell P (2007) Clinical update: new treatments for age-related macular degeneration. Lancet 370:204\u2013206","journal-title":"Lancet"},{"key":"709_CR24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.preteyeres.2009.10.001","volume":"29","author":"A Laude","year":"2010","unstructured":"Laude A, Cackett P, Vithana E, Yeo I, Wong D, Koh A, Wong T, Aung T (2010) Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retin Eye Res 29:19\u201329","journal-title":"Prog Retin Eye Res"},{"key":"709_CR25","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1167\/iovs.08-2510","volume":"50","author":"M Funk","year":"2009","unstructured":"Funk M, Kriechbaum K, Prager F, Benesch T, Georgopoulos M, Zlabinger GJ, Schmidt-Erfurth U (2009) Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 50:1025\u20131032","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"709_CR26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ophtha.2008.09.036","volume":"116","author":"MI Roh","year":"2009","unstructured":"Roh MI, Kim HS, Song JH, Lim JB, Kwon OW (2009) Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema. Ophthalmology 116:80\u201386","journal-title":"Ophthalmology"},{"key":"709_CR27","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.ophtha.2008.12.024","volume":"116","author":"N Arimura","year":"2009","unstructured":"Arimura N, Otsuka H, Yamakiri K, Sonoda Y, Nakao S, Noda Y, Hashiguchi T, Maruyama I, Sakamoto T (2009) Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. Ophthalmolgy 116:921\u2013926","journal-title":"Ophthalmolgy"},{"key":"709_CR28","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMcibr0804551","volume":"359","author":"LP Aiello","year":"2008","unstructured":"Aiello LP (2008) Targeting intraocular neovascularization and edema\u2014one drop at a time. N Engl J Med 359:967\u2013969","journal-title":"N Engl J Med"},{"key":"709_CR29","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1167\/iovs.08-2871","volume":"50","author":"B Avci","year":"2009","unstructured":"Avci B, Avci R, Inan UU, Kaderli B (2009) Comparative evaluation of apoptotic activity in photoreceptor cells after intravitreal injection of bevacizumab and pegaptanib sodium in rabbits. Invest Ophthalmol Vis Sci 50:3438\u20133446","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"709_CR30","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1167\/iovs.09-4144","volume":"51","author":"SH Byeon","year":"2010","unstructured":"Byeon SH, Lee SC, Choi SH, Lee HK, Lee JH, Chu YK, Kwon OW (2010) Vascular endothelial growth factor as an autocrine survival factor for retinal pigment epithelial cells under oxidative stress via the VEGF-R2\/PI3K\/Akt. Invest Ophthalmol Vis Sci 51:1190\u20131197","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"709_CR31","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1167\/iovs.06-0828","volume":"48","author":"UU Inan","year":"2007","unstructured":"Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R, Temel SG (2007) Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 48:1773\u20131781","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"709_CR32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2353\/ajpath.2007.061237","volume":"171","author":"K Nishijima","year":"2007","unstructured":"Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP et al (2007) Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171:53\u201367","journal-title":"Am J Pathol"},{"key":"709_CR33","doi-asserted-by":"crossref","first-page":"18751","DOI":"10.1073\/pnas.0905010106","volume":"106","author":"M Saint-Geniez","year":"2009","unstructured":"Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D'Amore PA (2009) An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci U S A 106:18751\u201318756","journal-title":"Proc Natl Acad Sci U S A"},{"key":"709_CR34","doi-asserted-by":"crossref","first-page":"e3554","DOI":"10.1371\/journal.pone.0003554","volume":"3","author":"M Saint-Geniez","year":"2008","unstructured":"Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, Darland DC, Young MJ, D\u2019Amore PA (2008) Endogenous VEGF is required for visual function: evidence for a survival role on m\u00fcller cells and photoreceptors. PLoS One 3:e3554","journal-title":"PLoS One"},{"key":"709_CR35","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/STROKEAHA.109.574475","volume":"41","author":"TY Wong","year":"2010","unstructured":"Wong TY (2010) Age-related macular degeneration: why should stroke physicians care? Stroke 41:575\u2013576","journal-title":"Stroke"},{"key":"709_CR36","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1517\/14740330903418422","volume":"9","author":"U Schmidt-Erfurth","year":"2010","unstructured":"Schmidt-Erfurth U (2010) Clinical safety of ranibizumab in age-related macular degeneration. Exp Opin Drug Saf 9:149\u2013165","journal-title":"Exp Opin Drug Saf"},{"key":"709_CR37","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1007\/s00417-005-0199-9","volume":"244","author":"PK Kaiser","year":"2006","unstructured":"Kaiser PK, TS Group (2006) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8. Graefes Arch Clin Exp Ophthalmol 244:1132\u20131142","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"709_CR38","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/bjo.2005.089458","volume":"91","author":"RW Essex","year":"2007","unstructured":"Essex RW, Tufail A, Bunce C, Aylward GW (2007) Two-year results of surgical removal of choroidal neovascular membranes related to non-age-related macular degeneration. Br J Ophthalmol 91:649\u2013654","journal-title":"Br J Ophthalmol"},{"key":"709_CR39","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1568007054546162","volume":"4","author":"EC Leal","year":"2005","unstructured":"Leal EC, Santiago AR, Ambr\u00f3sio AF (2005) Old and new drug targets in diabetic retinopathy: from biochemical changes to inflammation and neurodegeneration. Curr Drug Targets CNS Neurol Disord 4:421\u2013434","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"709_CR40","doi-asserted-by":"crossref","first-page":"e4160","DOI":"10.1371\/journal.pone.0004160","volume":"4","author":"AL Wang","year":"2009","unstructured":"Wang AL, Lukas TJ, Yuan M, Du N, Tso MO, Neufeld AH (2009) Autophagy and exosomes in the aged retinal pigment epithelium: possible relevance to drusen formation and age-related macular degeneration. PLoS One 4:e4160","journal-title":"PLoS One"},{"key":"709_CR41","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000108117","volume":"39","author":"SH Kim","year":"2007","unstructured":"Kim SH, Lutz RJ, Wang NS, Robinson MR (2007) Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res 39:244\u2013254","journal-title":"Ophthalmic Res"},{"key":"709_CR42","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1177\/112067210601600521","volume":"16","author":"M Nicol\u00f2","year":"2006","unstructured":"Nicol\u00f2 M, Ghiglione D, Calabria G (2006) Retinal pigment epithelial tear following intravitreal injection of bevacizumab (Avastin). Eur J Ophthalmol 16:770\u2013773","journal-title":"Eur J Ophthalmol"},{"key":"709_CR43","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.ajo.2006.07.037","volume":"142","author":"CP Shah","year":"2006","unstructured":"Shah CP, Hsu J, Garg SJ, Fischer DH, Kaiser R (2006) Retinal pigment epithelial tear after intravitreal bevacizumab injection. Am J Ophthalmol 142:1070\u20131072","journal-title":"Am J Ophthalmol"},{"key":"709_CR44","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/00006982-200310000-00014","volume":"23","author":"ML Nelson","year":"2003","unstructured":"Nelson ML, Tennant MT, Sivalingam A, Regillo CD, Belmont JB, Martidis A (2003) Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 23:686\u2013691","journal-title":"Retina"},{"key":"709_CR45","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/archopht.121.9.1279","volume":"121","author":"DB Roth","year":"2003","unstructured":"Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA (2003) Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 121:1279\u20131282","journal-title":"Arch Ophthalmol"},{"key":"709_CR46","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0008-4182(05)80119-X","volume":"40","author":"A Ozkiri\u015f","year":"2005","unstructured":"Ozkiri\u015f A, Erkili\u00e7 K (2005) Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol 40:63\u201368","journal-title":"Can J Ophthalmol"},{"key":"709_CR47","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1210\/en.143.7.2797","volume":"143","author":"C Wulff","year":"2002","unstructured":"Wulff C, Wilson H, Wiegand SJ, Rudge JS, Fraser HM (2002) Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. Endocrinology 143:2797\u20132807","journal-title":"Endocrinology"},{"key":"709_CR48","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","volume":"99","author":"J Holash","year":"2002","unstructured":"Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E et al (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. PNAS 99:11393\u201311398","journal-title":"PNAS"},{"key":"709_CR49","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000228926","volume":"223","author":"Z Ni","year":"2009","unstructured":"Ni Z, Hui P (2009) Emerging pharmacologic therapies for wet age-related macular degeneration. Ophthalmologica 223:401\u2013410","journal-title":"Ophthalmologica"},{"key":"709_CR50","doi-asserted-by":"crossref","first-page":"11131","DOI":"10.1073\/pnas.211268598","volume":"98","author":"M Simonovic","year":"2001","unstructured":"Simonovic M, Gettins PG, Volz K (2001) Crystal structure of human PEDF, a potent anti-angiogenic and neurite growth-promoting factor. Proc Natl Acad Sci U S A 98:11131\u201311135","journal-title":"Proc Natl Acad Sci U S A"},{"key":"709_CR51","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/hum.2006.17.167","volume":"17","author":"PA Campochiaro","year":"2006","unstructured":"Campochiaro PA, Nguyen QD, Shah SM, Klein ML, Holz E, Frank RN, Saperstein DA, Gupta A, Stout JT, Macko J et al (2006) Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 17:167\u2013176","journal-title":"Hum Gene Ther"},{"key":"709_CR52","first-page":"2029","volume":"12","author":"H Rasmussen","year":"2001","unstructured":"Rasmussen H, Chu KW, Campochiaro P, Gehlbach PL, Haller JA, Handa JT, Nguyen QD, Sung JU (2001) Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther 12:2029\u20132032","journal-title":"Hum Gene Ther"},{"key":"709_CR53","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","volume":"80","author":"SE Raper","year":"2003","unstructured":"Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, Wilson JM, Batshaw ML (2003) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80:148\u2013158","journal-title":"Mol Genet Metab"},{"key":"709_CR54","unstructured":"Wei L, Hamilton M, McVey D, King C, Brough D (2004) Repeat dosing of adenovector in the eye. ARVO 2004 Meeting Poster presentation. Available at: http:\/\/www.genvec.com\/download\/1hamilton_04_web.pdf ."},{"key":"709_CR55","unstructured":"Wei L (2007) Clinical trial in age-related macular degeneration. American Society for Gene Therapy Annual Meeting 2007 Oral Presentation. Available at: http:\/\/www.genvec.com\/download\/2007%2020ASGT%2020Wei%2020Clin%2020Trial%2020in%2020AMD%2020with%2020AdPEDF%2020-%2020Final%2020Out.pdf ."},{"key":"709_CR56","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","volume":"117","author":"J Haller","year":"2010","unstructured":"Haller J, Bandello F, Belfort RJ, Blumenkranz M, Gillies M, Heier J, Loewenstein A, Yoon Y, Jacques M, Jiao J et al (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117:1134\u20131146.e1","journal-title":"Ophthalmology"},{"key":"709_CR57","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archophthalmol.2010.21","volume":"128","author":"JA Haller","year":"2010","unstructured":"Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, Whitcup SM, DDPIS Group (2010) Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 128:289\u2013296","journal-title":"Arch Ophthalmol"},{"key":"709_CR58","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","volume":"117","author":"JA Haller","year":"2010","unstructured":"Haller JA, Bandello F, Belfort RJ, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J et al (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Opthalmology 117:1134\u20131146.e1","journal-title":"Opthalmology"},{"key":"709_CR59","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1021\/jm800566m","volume":"51","author":"P Harris","year":"2008","unstructured":"Harris P, Boloor A, Cheung M, Kumar R, Crosby R, Davis-Ward R, Epperly A, Hinkle K, Rr H, Johnson J et al (2008) Discovery of 5-[[4-[(2, 3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 51:4632\u20134640","journal-title":"J Med Chem"},{"key":"709_CR60","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/1535-7163.MCT-07-0193","volume":"6","author":"R Kumar","year":"2007","unstructured":"Kumar R, Knick V, Rudolph S, Johnson J, Crosby R, Crouthamel M, Hopper T, Miller C, Harrington L, Onori J et al (2007) Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 6:2012\u20132021","journal-title":"Mol Cancer Ther"},{"key":"709_CR61","unstructured":"McLaughlin M (2010) Pazopanib eye drops for neovascular AMD. GTCbio 2nd Annual Ocular Diseases and Drug Discovery Conference (Keynote presentation abstract)"},{"key":"709_CR62","unstructured":"Pazopanib ct ID# NCT00612456 and # NCT01154062. Available at: www.clinicaltrials.gov . Accessed 18 September 2010"},{"key":"709_CR63","unstructured":"OT-551 fDA (2009) OTHERA announces positive interim phase 2 results of OT-551 eye drop treatment for dry AMD. Available at: http:\/\/www.medicalnewstoday.com\/articles\/145919.php . Accessed 4 October 2009"},{"key":"709_CR64","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1101\/gad.1228704","volume":"18","author":"MS Hayden","year":"2004","unstructured":"Hayden MS, Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 18:2195\u20132224","journal-title":"Genes Dev"},{"key":"709_CR65","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2008.01.020","volume":"132","author":"MS Hayden","year":"2008","unstructured":"Hayden MS, Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell 132:344\u2013362","journal-title":"Cell"},{"key":"709_CR66","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1146\/annurev.immunol.021908.132641","volume":"27","author":"S Vallabhapurapu","year":"2009","unstructured":"Vallabhapurapu S, Karin M (2009) Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 27:693\u2013733","journal-title":"Annu Rev Immunol"},{"key":"709_CR67","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.gene.2009.01.003","volume":"435","author":"DA Johnston","year":"2009","unstructured":"Johnston DA, Dong B, Hughes CC (2009) TNF induction of jagged-1 in endothelial cells is NFkappaB-dependent. Gene 435:36\u201344","journal-title":"Gene"},{"issue":"12","key":"709_CR68","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.1167\/iovs.10-5637","volume":"51","author":"W Wong","year":"2010","unstructured":"Wong W, Kam W, Cunningham D, Harrington M, Hammel K, Meyerle C, Cukras C, Chew E, Sadda S, Ferris F (2010) Treatment of geographic atrophy by the topical administration of OT-551: results of a phase ii clinical trial. Invest Ophthalmol Vis Sci 51(12):6131\u20136139","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"709_CR69","unstructured":"TG100801 (2010) ID # NCT00509548. Available at: www.clinicaltrials.gov"},{"key":"709_CR70","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jcp.21426","volume":"216","author":"J Doukas","year":"2008","unstructured":"Doukas J, Mahesh S, Umeda N, Kachi S, Akiyama H, Yokoi K, Cao J, Chen Z, Dellamary L, Tam B et al (2008) Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol 216:29\u201337","journal-title":"J Cell Physiol"},{"key":"709_CR71","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2125.2004.02194.x","volume":"58","author":"DK Walter","year":"2004","unstructured":"Walter DK (2004) The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. Br J Clin Pharmacol 58:601\u2013608","journal-title":"Br J Clin Pharmacol"},{"key":"709_CR72","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","volume":"351","author":"ES Gragoudas","year":"2004","unstructured":"Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, VISiONCT Group (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805\u20132816","journal-title":"N Engl J Med"},{"key":"709_CR73","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002512-200724080-00003","volume":"24","author":"M Waisbourd","year":"2007","unstructured":"Waisbourd M, Loewenstein A, Goldstein M, Leibovitch I (2007) Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration. Drugs Aging 24:643\u2013662","journal-title":"Drugs Aging"},{"key":"709_CR74","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1517\/13543776.17.11.1351","volume":"17","author":"M-A Gamulescu","year":"2007","unstructured":"Gamulescu M-A, Helbig H (2007) A new era in the treatment of age-related macular degeneration. Expert Opin Ther Patents 17:1351\u20131363","journal-title":"Expert Opin Ther Patents"},{"key":"709_CR75","unstructured":"Roberts D (2008) New anti-PDGF aptamer now in trials. Available at: http:\/\/www.mdsupport.org\/library\/E10030.html Accessed 15 February 2010."},{"key":"709_CR76","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1096\/fj.03-0271fje","volume":"18","author":"R Erber","year":"2004","unstructured":"Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P (2004) Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 18:338\u2013340","journal-title":"FASEB J"},{"key":"709_CR77","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ydbio.2003.08.015","volume":"264","author":"DC Darland","year":"2003","unstructured":"Darland DC, Massingham LJ, Smith SR, Piek E, Saint-Geniez M, D\u2019Amore PA (2003) Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev Biol 264:275\u2013288","journal-title":"Dev Biol"},{"key":"709_CR78","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","volume":"8","author":"G Bergers","year":"2008","unstructured":"Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592\u2013603","journal-title":"Nat Rev Cancer"},{"key":"709_CR79","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.bcmd.2006.12.003","volume":"38","author":"ZK Otrock","year":"2007","unstructured":"Otrock ZK, Makarem JA, Shamseddine AI (2007) Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis 38:258\u2013268","journal-title":"Blood Cells Mol Dis"},{"key":"709_CR80","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature05571","volume":"445","author":"M Hellstr\u00f6m","year":"2007","unstructured":"Hellstr\u00f6m M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N et al (2007) Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445:776\u2013780","journal-title":"Nature"},{"key":"709_CR81","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1073\/pnas.0611206104","volume":"104","author":"IB Lobov","year":"2007","unstructured":"Lobov IB, Renard RA, Papadopoulos N, Gale NW, Thurston G, Yancopoulos GD, Wiegand SJ (2007) Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci U S A 104:3219\u20133224","journal-title":"Proc Natl Acad Sci U S A"},{"key":"709_CR82","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1073\/pnas.0611177104","volume":"104","author":"S Suchting","year":"2007","unstructured":"Suchting S, Freitas C, le Noble F, Benedito R, Br\u00e9ant C, Duarte A, Eichmann A (2007) The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc Natl Acad Sci U S A 104:3225\u20133230","journal-title":"Proc Natl Acad Sci U S A"},{"key":"709_CR83","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature07083","volume":"454","author":"T Tammela","year":"2008","unstructured":"Tammela T, Zarkada G, Wallgard E, Murtom\u00e4ki A, Suchting S, Wirzenius M, Waltari M, Hellstr\u00f6m M, Schomber T, Peltonen R et al (2008) Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454:656\u2013660","journal-title":"Nature"},{"key":"709_CR84","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ajo.2009.02.012","volume":"148","author":"M Cho","year":"2009","unstructured":"Cho M, Barbazetto I, Freund K (2009) Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol 148:70\u201378.e71","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"709_CR85","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ajo.2010.05.035","volume":"150","author":"A Stangos","year":"2010","unstructured":"Stangos A, Gandhi J, Nair-Sahni J, Heimann H, Pournaras C, Harding S (2010) Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. Am J Ophthalmol 150(5):666\u2013673","journal-title":"Am J Ophthalmol"},{"key":"709_CR86","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1126\/science.1110189","volume":"308","author":"AO Edwards","year":"2005","unstructured":"Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA (2005) Complement factor H polymorphism and age-related macular degeneration. Science 308:421\u2013424","journal-title":"Science"},{"key":"709_CR87","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/ejhg.2008.140","volume":"17","author":"JA Fagerness","year":"2009","unstructured":"Fagerness JA, Maller JB, Neale BM, Reynolds RC, Daly MJ, Seddon JM (2009) Variation near complement factor I is associated with risk of advanced AMD. Eur J Hum Genet 17:100\u2013104","journal-title":"Eur J Hum Genet"},{"key":"709_CR88","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/ng1750","volume":"38","author":"B Gold","year":"2006","unstructured":"Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AJ, Gehrs K, Cramer K, Neel J, Bergeron J, Barile GR et al (2006) Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet 38:458\u2013462","journal-title":"Nat Genet"},{"key":"709_CR89","doi-asserted-by":"crossref","first-page":"7227","DOI":"10.1073\/pnas.0501536102","volume":"102","author":"GS Hageman","year":"2005","unstructured":"Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, Hageman JL, Stockman HA, Borchardt JD, Gehrs KM et al (2005) A common haplotype in the complement regulatory gene factor H (HF1\/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A 102:7227\u20137232","journal-title":"Proc Natl Acad Sci U S A"},{"key":"709_CR90","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1056\/NEJMoa072618","volume":"357","author":"JR Yates","year":"2007","unstructured":"Yates JR, Sepp T, Matharu BK, Khan JC, Thurlby DA, Shahid H, Clayton DG, Hayward C, Morgan J, Wright AF et al (2007) Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 357:553\u2013561","journal-title":"N Engl J Med"},{"key":"709_CR91","doi-asserted-by":"crossref","first-page":"17456","DOI":"10.1073\/pnas.0606234103","volume":"103","author":"PT Johnson","year":"2006","unstructured":"Johnson PT, Betts KE, Radeke MJ, Hageman GS, Anderson DH, Johnson LV (2006) Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid. Proc Natl Acad Sci U S A 103:17456\u201317461","journal-title":"Proc Natl Acad Sci U S A"},{"key":"709_CR92","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1073\/pnas.0408835103","volume":"103","author":"M Nozaki","year":"2006","unstructured":"Nozaki M, Raisler BJ, Sakurai E, Sarma JV, Barnum SR, Lambris JD, Chen Y, Zhang K, Ambati BK, Baffi JZ et al (2006) Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A 103:2328\u20132333","journal-title":"Proc Natl Acad Sci U S A"},{"key":"709_CR93","unstructured":"Potentia Pharmaceuticals\u2019 POT-4 Drug Candidate For Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial. May 5, 2009. http:\/\/www.medicalnewstoday.com\/articles\/148725.php Accessed 30\/09\/09"},{"key":"709_CR94","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/sonc.2002.37264","volume":"29","author":"N Ferrara","year":"2002","unstructured":"Ferrara N (2002) Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29:10\u201314","journal-title":"Semin Oncol"},{"key":"709_CR95","doi-asserted-by":"crossref","unstructured":"Praidou A, Papakonstantinou E, Androudi S, Georgiadis N, Karakiulakis G, Dimitrakos S (2009) Vitreous and serum levels of vascular endothelial growth factor and platelet-derived growth factor and their correlation in patients with non-proliferative diabetic retinopathy and clinically significant macula oedema. Acta Ophthalmol (in press)","DOI":"10.1080\/02713680802585920"},{"key":"709_CR96","first-page":"323","volume":"19","author":"M Lu","year":"2006","unstructured":"Lu M, Adamis AP (2006) Molecular biology of choroidal neovascularization. Ophthalmol Clin North Am 19:323\u2013334","journal-title":"Ophthalmol Clin North Am"},{"key":"709_CR97","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/1573399052952596","volume":"1","author":"Y Mitamura","year":"2005","unstructured":"Mitamura Y, Harada C, Harada T (2005) Role of cytokines and trophic factors in the pathogenesis of diabetic retinopathy. Curr Diabetes Rev 1:73\u201381","journal-title":"Curr Diabetes Rev"},{"key":"709_CR98","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF01745169","volume":"11","author":"K Shinohara","year":"1996","unstructured":"Shinohara K, Shinohara T, Mochizuki N, Mochizuki Y, Sawa H, Kohya T, Fujita M, Fujioka Y, Kitabatake A, Nagashima K (1996) Expression of vascular endothelial growth factor in human myocardial infarction. Heart Vessels 11:113\u2013122","journal-title":"Heart Vessels"},{"key":"709_CR99","doi-asserted-by":"crossref","first-page":"12439","DOI":"10.1523\/JNEUROSCI.0434-06.2006","volume":"26","author":"U Kilic","year":"2006","unstructured":"Kilic U, Kilic E, J\u00e4rve A, Guo Z, Spudich A, Bieber K, Barzena U, Bassetti CL, Marti HH, Hermann DM (2006) Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1\/2 and Akt pathways. J Neurosci 26:12439\u201312446","journal-title":"J Neurosci"},{"key":"709_CR100","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000088637","volume":"14","author":"I Zachery","year":"2005","unstructured":"Zachery I (2005) Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. Neurosignals 14:207\u2013221","journal-title":"Neurosignals"},{"key":"709_CR101","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1172\/JCI2425","volume":"102","author":"AJ Barber","year":"1998","unstructured":"Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW (1998) Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Inves 102:783\u2013791","journal-title":"J Clin Inves"},{"key":"709_CR102","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0278-5846(03)00023-X","volume":"27","author":"AJ Barber","year":"2003","unstructured":"Barber AJ (2003) A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry 27:283\u2013290","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"709_CR103","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1016\/j.biocel.2009.07.011","volume":"41","author":"X Zhang","year":"2009","unstructured":"Zhang X, Bao S, Hambly BD, Gillies MC (2009) Vascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathy. Int J Biochem Cell Biol 41:2368\u20132371","journal-title":"Int J Biochem Cell Biol"},{"key":"709_CR104","first-page":"353","volume":"58","author":"JZ Nowak","year":"2006","unstructured":"Nowak JZ (2006) Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 58:353\u2013363","journal-title":"Pharmacol Rep"},{"key":"709_CR105","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1001\/archopht.120.11.1435","volume":"120","author":"J Dunaief","year":"2002","unstructured":"Dunaief J, Dentchev T, Ying G, Milam A (2002) The role of apoptosis in age-related macular degeneration. Arch Ophthalmol 120:1435\u20131442","journal-title":"Arch Ophthalmol"},{"key":"709_CR106","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/414813a","volume":"414","author":"M Brownlee","year":"2001","unstructured":"Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813\u2013820","journal-title":"Nature"},{"key":"709_CR107","first-page":"1301","volume":"22","author":"JK Shen","year":"2007","unstructured":"Shen JK, Dong A, Hackett SF, Bell WR, Green WR, Campochiaro PA (2007) Oxidative damage in age-related macular degeneration. Histol Histopathol 22:1301\u20131308","journal-title":"Histol Histopathol"},{"key":"709_CR108","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1476-5381.2008.00086.x","volume":"156","author":"Szabo","year":"2009","unstructured":"Szabo (2009) Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction. Br J Pharmacol 156:714\u2013727","journal-title":"Br J Pharmacol"},{"key":"709_CR109","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1167\/iovs.05-1229","volume":"47","author":"M Saint-Geniez","year":"2006","unstructured":"Saint-Geniez M, Maldonado AE, D\u2019Amore PA (2006) VEGF expression and receptor activation in the choroid during development and in the adult. Invest Ophthalmol Vis Sci 47:3135\u20133142","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"709_CR110","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1136\/bjo.2006.108795","volume":"91","author":"S Gibran","year":"2007","unstructured":"Gibran S, Sachdev A, Stappler T, Newsome R, Wong D, Hiscott P (2007) Histological findings of a choroidal neovascular membrane removed at the time of macular translocation in a patient previously treated with intravitreal bevacizumab treatment (Avastin). Br J Ophthalmol 91:602\u2013604","journal-title":"Br J Ophthalmol"},{"key":"709_CR111","doi-asserted-by":"crossref","unstructured":"Rosenfeld P, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B, Groups MaAS (2010) Characteristics of patients losing vision after 2\u00a0years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology (in press)","DOI":"10.1016\/j.ophtha.2010.07.011"},{"key":"709_CR112","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/jcp.22129","volume":"224","author":"A Miki","year":"2010","unstructured":"Miki A, Miki K, Ueno S, Wersinger D, Berlinicke C, Shaw G, Usui S, Wang Y, Zack D, Campochiaro P (2010) Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells. J Cell Physiol 224:262\u2013272","journal-title":"J Cell Physiol"},{"key":"709_CR113","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1167\/iovs.07-1542","volume":"50","author":"K Sakurai","year":"2009","unstructured":"Sakurai K, Akiyama H, Shimoda Y, Yoshida I, Kurabayashi M, Kishi S (2009) Effect of intravitreal injection of high-dose bevacizumab in monkey eyes. Invest Ophthalmol Vis Sci 50:4905\u20134916","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"709_CR114","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1111\/j.1755-3768.2010.01927.x","volume":"88","author":"S Thaler","year":"2010","unstructured":"Thaler S, Fiedorowicz M, Choragiewicz T, Bolz S, Tura A, Henke-Fahle S, Yoeruek E, Zrenner E, Bartz-Schmidt K, Ziemssen F et al (2010) Toxicity testing of the VEGF inhibitors bevacizumab, ranibizumab and pegaptanib in rats both with and without prior retinal ganglion cell damage. Acta Ophthalmol 88:e170\u2013e176","journal-title":"Acta Ophthalmol"},{"key":"709_CR115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jcp.21445","volume":"217","author":"S Ueno","year":"2008","unstructured":"Ueno S, Pease M, Wersinger D, Masuda T, Vinores S, Licht T, Zack D, Quigley H, Keshet E, Campochiaro P (2008) Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels. J Cell Physiol 217:13\u201322","journal-title":"J Cell Physiol"},{"key":"709_CR116","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/IAE.0b013e3181c0858c","volume":"30","author":"S Zayit-Soudry","year":"2010","unstructured":"Zayit-Soudry S, Zemel E, Loewenstein A, Perlman I (2010) Safety evaluation of repeated intravitreal injections of bevacizumab and ranibizumab in rabbit eyes. Retina 30:671\u2013681","journal-title":"Retina"},{"key":"709_CR117","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nature06765","volume":"452","author":"ME Kleinman","year":"2008","unstructured":"Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ, Albuquerque RJ, Yamasaki S, Itaya M, Pan Y et al (2008) Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452:591\u2013597","journal-title":"Nature"},{"key":"709_CR118","unstructured":"Macron D (2009) As it matures, RNAi field sees failures of key clinical candidates. June 11, 2009 Genome web RNAi News. Available at: http:\/\/www.genomeweb.com\/rnai\/it-matures-rnai-field-sees-failures-key-clinical-candidates . Accessed 12 October 2009"},{"key":"709_CR119","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1167\/iovs.08-3303","volume":"50","author":"G Jiang","year":"2009","unstructured":"Jiang G, Ke Y, Sun D, Wang Y, Kaplan H, Shao H (2009) Regulatory role of TLR ligands on the activation of autoreactive T cells by retinal astrocytes. Invest Ophthalmol Vis Sci 50:4769\u20134776","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"709_CR120","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa0802437","volume":"359","author":"Z Yang","year":"2008","unstructured":"Yang Z, Stratton C, Francis P, Kleinman M, Tan P, Gibbs D, Tong Z, Chen H, Constantine R, Yang X et al (2008) Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. N Engl J Med 359:1456\u20131463","journal-title":"N Engl J Med"},{"key":"709_CR121","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1161\/01.STR.28.3.564","volume":"28","author":"J Krupinski","year":"1997","unstructured":"Krupinski J, Issa R, Bujny T, Slevin M, Kumar P, Kumar S, Kaluza J (1997) A putative role for platelet-derived growth factor in angiogenesis and neuroprotection after ischemic stroke in humans. Stroke 28:564\u2013573","journal-title":"Stroke"},{"key":"709_CR122","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0165-0173(97)00012-X","volume":"24","author":"CF Valenzuela","year":"1997","unstructured":"Valenzuela CF, Kazlauskas A, Weiner JL (1997) Roles of platelet-derived growth factor in the developing and mature nervous systems. Brain Res Brain Res Rev 24:77\u201389","journal-title":"Brain Res Brain Res Rev"},{"key":"709_CR123","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/nm.2052","volume":"15","author":"P Geraldes","year":"2009","unstructured":"Geraldes P, Hiraoka-Yamamoto J, Matsumoto M, Clermont A, Leitges M, Marette A, Aiello LP, Kern TS, King GL (2009) Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med 15:1298\u20131306","journal-title":"Nat Med"},{"key":"709_CR124","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0092-8674(00)00117-3","volume":"103","author":"T Schmelzle","year":"2000","unstructured":"Schmelzle T, Hall MN (2000) TOR, a central controller of cell growth. Cell 103:253\u2013262","journal-title":"Cell"},{"key":"709_CR125","first-page":"964","volume":"10","author":"NS Dejneka","year":"2004","unstructured":"Dejneka NS, Kuroki AM, Fosnot J, Tang W, Tolentino MJ, Bennett J (2004) Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis 10:964\u2013972","journal-title":"Mol Vis"},{"key":"709_CR126","unstructured":"MacuSight (2009) Innovative therapeutics for the treatment of severe diseases and conditions of the eye: MacuSight. Ophthalmology Innovation Summit Presentation. Available at: http:\/\/www.ophthalmologysummit.com\/presentations\/Macusight.pdf ."},{"key":"709_CR127","unstructured":"Perceiva cct ID# NCT00656643, # NCT00711490 and # NCT00766649. Available at: www.clinicaltrials.gov . Accessed 18 September 2010"},{"key":"709_CR128","unstructured":"Perceiva tt ID# NCT00712491 and # NCT00766337. Available at: www.clinicaltrials.gov . Accessed 18 September 2010"},{"key":"709_CR129","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nn.2234","volume":"12","author":"C Punzo","year":"2009","unstructured":"Punzo C, Kornacker K, Cepko CL (2009) Stimulation of the insulin\/mTOR pathway delays cone death in a mouse model of retinitis pigmentosa. Nat Neurosci 12:44\u201352","journal-title":"Nat Neurosci"},{"key":"709_CR130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0003-9861(02)00244-8","volume":"404","author":"A Dhillon","year":"2002","unstructured":"Dhillon A, Kolch W (2002) Untying the regulation of the Raf-1 kinase. Arch Biochem Biophys 404:3\u20139","journal-title":"Arch Biochem Biophys"},{"key":"709_CR131","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2337\/diabetes.53.3.775","volume":"53","author":"RA Kowluru","year":"2004","unstructured":"Kowluru RA, Kowluru A, Chakrabarti S, Khan Z (2004) Potential contributory role of H-Ras, a small G-protein, in the development of retinopathy in diabetic rats. Diabetes 53:775\u2013783","journal-title":"Diabetes"},{"key":"709_CR132","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1172\/JCI0214268","volume":"110","author":"S Kim","year":"2002","unstructured":"Kim S, Bakre M, Yin H, Varner JA (2002) Inhibition of endothelial cell survival and angiogenesis by protein kinase A. J Clin Inves 110:933\u2013941","journal-title":"J Clin Inves"},{"key":"709_CR133","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0002-9440(10)65005-5","volume":"156","author":"S Kim","year":"2000","unstructured":"Kim S, Bell K, Mousa SA, Varner JA (2000) Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 156:1345\u20131362","journal-title":"Am J Pathol"},{"key":"709_CR134","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/jcb.20488","volume":"95","author":"BH Lee","year":"2005","unstructured":"Lee BH, Ruoslahti E (2005) alpha5beta1 integrin stimulates Bcl-2 expression and cell survival through Akt, focal adhesion kinase, and Ca2+\/calmodulin-dependent protein kinase IV. J cell Biochem 95:1214\u20131223","journal-title":"J cell Biochem"},{"key":"709_CR135","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1073\/pnas.98.2.620","volume":"98","author":"M Yi","year":"2001","unstructured":"Yi M, Ruoslahti E (2001) A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. Proc Natl Acad Sci U S A 98:620\u2013624","journal-title":"Proc Natl Acad Sci U S A"},{"key":"709_CR136","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ajo.2009.06.014","volume":"148","author":"K Csaky","year":"2009","unstructured":"Csaky K, Do DV (2009) Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol 148:647\u2013656","journal-title":"Am J Ophthalmol"},{"key":"709_CR137","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1517\/17425247.3.2.275","volume":"3","author":"D Ghate","year":"2006","unstructured":"Ghate D, Edelhauser HF (2006) Ocular drug delivery. Expert Opin Drug Deli 3:275\u2013287","journal-title":"Expert Opin Drug Deli"},{"key":"709_CR138","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1167\/iovs.09-4140","volume":"51","author":"MT SO","year":"2010","unstructured":"SO MT, Kakinoki M, Sawada T, Kawamura H, Ogasawara K, Ohji M (2010) Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci 51:1606\u20131608","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"709_CR139","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2009.10.011","volume":"36","author":"JJ Gibbons","year":"2009","unstructured":"Gibbons JJ, Abraham RT, Yu K (2009) Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol 36:S3\u2013S17","journal-title":"Semin Oncol"},{"key":"709_CR140","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.2337\/db09-1324","volume":"59","author":"V Houde","year":"2010","unstructured":"Houde V, Br\u00fbl\u00e9 S, Festuccia W, Blanchard P, Bellmann K, Deshaies Y, Marette A (2010) Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 59:1338\u20131348","journal-title":"Diabetes"},{"key":"709_CR141","doi-asserted-by":"crossref","first-page":"s21","DOI":"10.1093\/ajhp\/61.suppl_5.S21","volume":"61","author":"RJ Ignoffo","year":"2004","unstructured":"Ignoffo RJ (2004) Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm 61:s21\u2013s26","journal-title":"Am J Health Syst Pharm"},{"key":"709_CR142","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nature08151","volume":"460","author":"A Takeda","year":"2009","unstructured":"Takeda A, Baffi JZ, Kleinman ME, Cho WG, Nozaki M, Yamada K, Kaneko H, Albuquerque RJ, Dridi S, Saito K et al (2009) CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature 460:225\u2013230","journal-title":"Nature"},{"key":"709_CR143","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1167\/iovs.08-3293","volume":"51","author":"J Kusari","year":"2010","unstructured":"Kusari J, Zhou SX, Padillo E, Clarke KG, Gil DW (2010) Inhibition of vitreoretinal VEGF elevation and blood\u2013retinal barrier breakdown in streptozotocin-induced diabetic rats by brimonidine. Invest Ophthalmol Vis Sci 51:1044\u20131051","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"709_CR144","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0022-3565(24)29683-X","volume":"296","author":"JE Donello","year":"2001","unstructured":"Donello JE, Padillo EU, Webster ML, Wheeler LA, Gil DW (2001) Alpha(2)-adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J Pharmacol Exp Ther 296:216\u2013223","journal-title":"J Pharmacol Exp Ther"},{"key":"709_CR145","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1167\/iovs.05-0392","volume":"46","author":"S Mayor-Torroglosa","year":"2005","unstructured":"Mayor-Torroglosa S, De la Villa P, Rodr\u00edguez ME, L\u00f3pez-Herrera MP, Avil\u00e9s-Trigueros M, Garc\u00eda-Avil\u00e9s A, de Imperial JM, Villegas-P\u00e9rez MP, Vidal-Sanz M (2005) Ischemia results 3\u00a0months later in altered ERG, degeneration of inner layers, and deafferented tectum: neuroprotection with brimonidine. Invest Ophthalmol Vis Sci 46:3825\u20133835","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"709_CR146","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.1016\/S0039-6257(01)00205-3","volume":"45","author":"M Vidal-Sanz","year":"2001","unstructured":"Vidal-Sanz M, Lafuente MP, Mayor S, de Imperial JM, Villegas-P\u00e9rez MP (2001) Retinal ganglion cell death induced by retinal ischemia. neuroprotective effects of two alpha-2 agonists. Surv Ophthalmol 45:S261\u2013S267","journal-title":"Surv Ophthalmol"},{"key":"709_CR147","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/jnci\/djh120","volume":"96","author":"G Zhang","year":"2004","unstructured":"Zhang G, Dass CR, Sumithran E, Di Girolamo N, Sun LQ, Khachigian LM (2004) Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. J Natl Cancer Inst 96:683\u2013696","journal-title":"J Natl Cancer Inst"},{"key":"709_CR148","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1242\/jcs.03059","volume":"119","author":"G Zhang","year":"2006","unstructured":"Zhang G, Fahmy RG, diGirolamo N, Khachigian LM (2006) JUN siRNA regulates matrix metalloproteinase-2 expression, microvascular endothelial growth and retinal neovascularisation. J Cell Sci 119:3219\u20133226","journal-title":"J Cell Sci"},{"key":"709_CR149","doi-asserted-by":"crossref","unstructured":"Fahmy RG, Waldman A, Zhang G, Mitchell A, Tedla N, Cai H, Geczy CR, Chesterman CN, Perry M, Khachigian LM (2006) Suppression of vascular permeability and inflammation by targeting of the transcription factor c-jun. Nat Biotechnol 24:856\u2013863","DOI":"10.1038\/nbt1225"},{"key":"709_CR150","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1161\/ATVBAHA.109.189753","volume":"29","author":"X Luo","year":"2009","unstructured":"Luo X, Cai H, Ni J, Bhindi R, Lowe HC, Chesterman CN, Khachigian LM (2009) c-Jun DNAzymes inhibit myocardial inflammation, ROS generation, infarct size, and improve cardiac function after ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol 29:1836\u20131842","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"709_CR151","doi-asserted-by":"crossref","first-page":"7260","DOI":"10.1038\/sj.onc.1209726","volume":"25","author":"G Zhang","year":"2006","unstructured":"Zhang G, Luo X, Sumithran E, Pua VS, Barnetson RS, Halliday GM, Khachigian LM (2006) Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression. Oncogene 25:7260\u20137266","journal-title":"Oncogene"},{"key":"709_CR152","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/bjo.2007.127142","volume":"92","author":"JF Arevalo","year":"2008","unstructured":"Arevalo JF, Maia M, Flynn HWJ, Saravia M, Avery RL, Wu L, Eid Farah M, Pieramici DJ, Berrocal MH, Sanchez JG (2008) Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92:213\u2013216","journal-title":"Br J Ophthalmol"},{"key":"709_CR153","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","volume":"246","author":"S Honda","year":"2008","unstructured":"Honda S, Hirabayashi H, Tsukahara Y, Negi A (2008) Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graedes Arch Clin Exp Ophthalmol 246:1061\u20131063","journal-title":"Graedes Arch Clin Exp Ophthalmol"},{"key":"709_CR154","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","volume":"118","author":"S Hacein-Bey-Abina","year":"2008","unstructured":"Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, Clappier E, Caccavelli L, Delabesse E, Beldjord K et al (2008) Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Inves 118:3132\u20133142","journal-title":"J Clin Inves"},{"key":"709_CR155","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1358\/dnp.2009.22.4.1367704","volume":"22","author":"G Romano","year":"2009","unstructured":"Romano G, Marino IR, Pentimalli F, Adamo V, Giordano A (2009) Insertional mutagenesis and development of malignancies induced by integrating gene delivery systems: implications for the design of safer gene-based interventions in patients. Drug News Perspect 22:185\u2013196","journal-title":"Drug News Perspect"},{"key":"709_CR156","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/nbt1007-1111","volume":"25","author":"MA Kay","year":"2007","unstructured":"Kay MA (2007) AAV vectors and tumorigenicity. Nat Biotechnol 25:1111\u20131113","journal-title":"Nat Biotechnol"},{"key":"709_CR157","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1128\/JVI.79.6.3606-3614.2005","volume":"79","author":"H Nakai","year":"2005","unstructured":"Nakai H, Wu X, Fuess S, Storm TA, Munroe D, Montini E, Burgess SM, Grompe M, Kay MA (2005) Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol 79:3606\u20133614","journal-title":"J Virol"},{"key":"709_CR158","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1371\/journal.pgen.0020133","volume":"2","author":"MH Porteus","year":"2006","unstructured":"Porteus MH, Connelly JP, Pruett SM (2006) A look to future directions in gene therapy research for monogenic diseases. PLOS Genet 2:e133","journal-title":"PLOS Genet"},{"key":"709_CR159","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(09)61836-5","volume":"374","author":"AM Maguire","year":"2009","unstructured":"Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F, Mingozzi F, Bennicelli JL, Ying GS, Rossi S et al (2009) Age-dependent effects of RPE65 gene therapy for Leber\u2019s congenital amaurosis: a phase 1 dose-escalation trial. Lancet 374:1597\u20131605","journal-title":"Lancet"},{"key":"709_CR160","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1128\/JVI.61.2.344-353.1987","volume":"61","author":"M Schulz","year":"1987","unstructured":"Schulz M, Freisem-Rabien U, Jessberger R, Doerfler W (1987) Transcriptional activities of mammalian genomes at sites of recombination with foreign DNA. J Virol 61:344\u2013353","journal-title":"J Virol"},{"key":"709_CR161","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1146\/annurev.genet.37.110801.143717","volume":"38","author":"DM McCarty","year":"2004","unstructured":"McCarty DM, Young SM Jr, Samulski RJ (2004) Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 38:819\u2013845","journal-title":"Annu Rev Genet"},{"key":"709_CR162","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1517\/14712598.6.7.717","volume":"6","author":"W Tao","year":"2006","unstructured":"Tao W (2006) Application of encapsulated cell technology for retinal degenerative diseases. Expert Opin Biol Ther 6:717\u2013726","journal-title":"Expert Opin Biol Ther"},{"key":"709_CR163","first-page":"3292","volume":"43","author":"W Tao","year":"2002","unstructured":"Tao W, Wen R, Goddard MB, Sherman SD, O'Rourke PJ, Stabila PF, Bell WJ, Dean BJ, Kauper KA, Budz VA et al (2002) Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci 43:3292\u20133298","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"709_CR164","unstructured":"Neurotech (2009) Results from neurotech\u2019s NT-501 phase 2 retinitis pigmentosa studies demonstrate consistent biological effect on photoreceptors. Available at: http:\/\/www.neurotechusa.com\/news_events\/pr_2009-05-28.asp Accessed 30 January 2010"},{"key":"709_CR165","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1167\/iovs.03-1342","volume":"45","author":"RA Bush","year":"2004","unstructured":"Bush RA, Lei B, Tao W, Raz D, Chan C, Cox TA, Santos-Muffley M, Sieving PA (2004) Encapsulated cell-based intraocular delivery of ciliary neurotrophic factor in normal rabbit: dose-dependent effects on ERG and retinal histology. Invest Ophthalmol Vis Sci 45:2420\u20132430","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"709_CR166","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1073\/pnas.0600236103","volume":"103","author":"PA Sieving","year":"2006","unstructured":"Sieving PA, Caruso RC, Tao W, Coleman HR, Thompson DJ, Fullmer KR, Bush RA (2006) Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A 103:3896\u20133901","journal-title":"Proc Natl Acad Sci U S A"},{"key":"709_CR167","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.exer.2005.07.014","volume":"82","author":"CJ Zeiss","year":"2006","unstructured":"Zeiss CJ, Allore HG, Towle V, Tao W (2006) CNTF induces dose-dependent alterations in retinal morphology in normal and rcd-1 canine retina. Exp Eye Res 82:395\u2013404","journal-title":"Exp Eye Res"},{"key":"709_CR168","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1350-9462(00)00025-2","volume":"20","author":"PL Penfold","year":"2001","unstructured":"Penfold PL, Madigan MC, Gillies MC, Provis JM (2001) Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res 20:385\u2013414","journal-title":"Prog Retin Eye Res"},{"key":"709_CR169","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/ICU.0b013e32832f8016","volume":"20","author":"AY Ting","year":"2009","unstructured":"Ting AY, Lee TK, MacDonald IM (2009) Genetics of age-related macular degeneration. Curr Opin Ophthalmol 20:369\u2013376","journal-title":"Curr Opin Ophthalmol"},{"key":"709_CR170","unstructured":"Positive Results from Neurotech\u2019s NT-501 Phase 2 Dry AMD (Geographic Atrophy) Study Demonstrate Proof of Concept. Available at: http:\/\/www.neurotechusa.com\/news_events\/pr_2009-03-26.asp Accessed 30 January 2010"},{"key":"709_CR171","unstructured":"NT-503. Available at: http:\/\/www.neurotechusa.com\/ect\/nt-503.asp . Accessed 20\/23\/10."},{"key":"709_CR172","unstructured":"Results from Neurotech\u2019s NT-501 phase 2 retinitis pigmentosa studies demonstrate consistent biological effect on photoreceptors. Available at: http:\/\/www.medicalnewstoday.com\/articles\/151786.php . Accessed 22 December 2009"},{"key":"709_CR173","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.2337\/db08-1327","volume":"58","author":"K Park","year":"2009","unstructured":"Park K, Chen Y, Hu Y, Mayo AS, Kompella UB, Longeras R, Ma JX (2009) Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage. Diabetes 58:1902\u20131913","journal-title":"Diabetes"},{"key":"709_CR174","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/sj.gt.3301318","volume":"7","author":"H Cohen","year":"2000","unstructured":"Cohen H, Levy RJ, Gao J, Fishbein I, Kousaev V, Sosnowski S, Slomkowski S, Golomb G (2000) Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles. Gene Ther 7:1896\u20131905","journal-title":"Gene Ther"},{"key":"709_CR175","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1096\/fj.02-0088com","volume":"16","author":"J Panyam","year":"2002","unstructured":"Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V (2002) Rapid endo-lysosomal escape of poly(dl-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J 16:1217\u20131226","journal-title":"FASEB J"},{"key":"709_CR176","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000053993","volume":"43","author":"BJ Ledwith","year":"2000","unstructured":"Ledwith BJ, Manam S, Troilo PJ, Barnum AB, Pauley CJ, Griffiths TG 2nd, Harper LB, Beare CM, Bagdon WJ, Nichols WW (2000) Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice. Intervirology 43:258\u2013272","journal-title":"Intervirology"},{"key":"709_CR177","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000053994","volume":"43","author":"S Manam","year":"2000","unstructured":"Manam S, Ledwith BJ, Barnum AB, Troilo PJ, Pauley CJ, Harper LB, Griffiths TG 2nd, Niu Z, Denisova L, Follmer TT et al (2000) Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. Intervirology 43:273\u2013281","journal-title":"Intervirology"},{"key":"709_CR178","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1749-6632.1995.tb44729.x","volume":"772","author":"WW Nichols","year":"1995","unstructured":"Nichols WW, Ledwith BJ, Manam SV, Troilo PJ (1995) Potential DNA vaccine integration into host cell genome. Ann N Y Acad Sci 772:30\u201339","journal-title":"Ann N Y Acad Sci"},{"key":"709_CR179","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.gt.3302213","volume":"11","author":"Z Wang","year":"2004","unstructured":"Wang Z, Troilo PJ, Wang X, Griffiths TG, Pacchione SJ, Barnum AB, Harper LB, Pauley CJ, Niu Z, Denisova L et al (2004) Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther 11:711\u2013721","journal-title":"Gene Ther"},{"key":"709_CR180","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/archophthalmol.2009.88","volume":"127","author":"G Davuluri","year":"2009","unstructured":"Davuluri G, Espina V, EFr P, Ross M, Deng J, Liotta LA, Glaser BM (2009) Activated VEGF receptor shed into the vitreous in eyes with wet AMD: a new class of biomarkers in the vitreous with potential for predicting the treatment timing and monitoring response. Arch Ophthalmol 127:613\u2013621","journal-title":"Arch Ophthalmol"},{"key":"709_CR181","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1200\/JCO.2007.12.0949","volume":"25","author":"LB Saltz","year":"2007","unstructured":"Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, Kemeny NE, Hollywood EM, Gonen M, Quinones M et al (2007) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25:4557\u20134561","journal-title":"J Clin Oncol"},{"key":"709_CR182","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/PPO.0b013e31815a7b69","volume":"13","author":"F Shojaei","year":"2007","unstructured":"Shojaei F, Ferrara N (2007) Antiangiogenic therapy for cancer: an update. Cancer J 13:345\u2013348","journal-title":"Cancer J"},{"key":"709_CR183","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.ophtha.2008.07.007","volume":"115","author":"S Schaal","year":"2008","unstructured":"Schaal S, Kaplan H, Tezel T (2008) Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 115:2199\u20132205","journal-title":"Ophthalmology"},{"key":"709_CR184","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/IAE.0b013e3181a2c1c3","volume":"29","author":"F Forooghian","year":"2009","unstructured":"Forooghian F, Cukras C, Meyerle C, Chew E, Wong W (2009) Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina 29:723\u2013731","journal-title":"Retina"},{"key":"709_CR185","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1167\/iovs.08-1689","volume":"49","author":"P Keane","year":"2008","unstructured":"Keane P, Liakopoulos S, Ongchin S, Heussen F, Msutta S, Chang K, Walsh A, Sadda S (2008) Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 49:3115\u20133120","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"709_CR186","unstructured":"Forooghian F, Chew E, Meyerle C, Cukras C, Wong W (2009) Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis. Acta Ophthalmol (in press)"},{"key":"709_CR187","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/jop.2009.0131","volume":"26","author":"Y Tao","year":"2010","unstructured":"Tao Y, Jonas J (2010) Intravitreal bevacizumab combined with intravitreal triamcinolone for therapy-resistant exudative age-related macular degeneration. J Ocul Pharmacol Ther 26:207\u2013212","journal-title":"J Ocul Pharmacol Ther"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-010-0709-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00109-010-0709-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-010-0709-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T22:34:30Z","timestamp":1740782070000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00109-010-0709-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,18]]},"references-count":187,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["709"],"URL":"https:\/\/doi.org\/10.1007\/s00109-010-0709-z","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,18]]}}}